La cadena de opciones muestra datos clave de las opciones de acciones de Lanvin Gr Hldgs a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Lanvin Gr Hldgs..

Lanvin Gr Hldgs (NYSE:LANV) Bolsa, Cadena de Opciones

Lanvin Gr Hldgs

Lanvin Group Holdings Ltd engages in offering products ranging from apparel to leather goods, footwear, and accessories. The firm is operating mainly 5 portfolio brands, namely Lanvin, Wolford, Sergio Rossi, St. John, and Caruso. It derives the majority of its revenue from the Wolford segment.

Lanvin Group Holdings Limited Ordinary Shares

Lanvin Group Holdings Ltd

Lanvin Group Holdings Limited Redeemable Warrants, each whole warrant exercisable for one Ordinary Share at an exercise price of $11.50

Needham analyst Quinn Bolton reiterated the Buy rating on D-Wave Quantum Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/QBTS#NYSE">QBTS</a>), <a href="https://www.benzinga.com/quote/QBTS/analyst-ratings" target="_blank" rel="noreferrer noopener">raising the price forecast from $8.50 to $13</a>.
On Thursday, the company reported revenue of $15 million for the quarter ended March 31, a more than sixfold increase on a year-over-year basis. The revenue boost was largely driven by the first recognized sale of its Advantage quantum computing system to a major research institution and increased client adoption of its hybrid quantum solutions.
Bolton pointed out several key developments.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45310899/quantum-computing-aids-energy-efficiency-for-blockchain-hashing-require-a-fraction-of-the-electricity-used-by-classical-resources-says-d-wave-ceo" rel="noreferrer noopener">Quantum Computing Aids Energy Efficiency For Blockchain Hashing: &#8216;Require A Fraction Of The Electricity Used By Classical Resources,&#8217; Says D-Wave CEO</a>
The sale of the Advantage system contributed to a strong revenue beat and a notable boost in next-generation gross margin, which came in at 93.6%, well above the Street estimate of 74.3%.
This indicates that system sales generate significantly higher margins compared to QCaaS revenue, the analyst writes.
The company also completed the installation of its Advantage2 system at Davidson in Alabama. Additionally, Bolton highlighted the company&#8217;s ongoing progress in quantum blockchain, including efforts to secure a partner for its go-to-market strategy.
Finally, the analyst noted that commercial interest has increased since the company&#8217;s quantum supremacy demonstration last quarter.
Bolton observed that D-Wave is making progress in the quantum blockchain space and is actively looking for a partner to help build a go-to-market strategy, which could lead to significant system sales opportunities if successful.
He mentioned that Ford Otosan is moving its deployment into production, with plans to expand across several factories.
According to Bolton, D-Wave&#8217;s growing technology portfolio and emphasis on practical, commercial use cases will likely drive stronger customer adoption and revenue growth.
However, he cautioned that since the company remains EBITDA-negative, investors should expect ongoing dilutive financing rounds until it reaches EBITDA break-even.
Price Action: QBTS shares are trading higher by 2.16% to $10.64 at last check Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/market-summary/25/05/45251508/warren-buffett-falls-behind-nancy-pelosi-in-stock-market-returns-over-the-last-11-years-heres-what-data-shows" target="_blank" rel="noreferrer noopener">Warren Buffett Falls Behind Nancy Pelosi In Stock Market Returns Over The Last 11 Years: Here&#8217;s What Data Shows</a></li>
</ul>
Photo: Shutterstock

Equities

News

Markets

Analyst Ratings

Movers

Trading Ideas

QBTS

D-Wave's Quantum Momentum Impresses Analyst, Sees Stronger Commercial Uptake Ahead

Goldman Sachs analyst Lizzie Dove maintains Six Flags Entertainment (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) with a Neutral and lowers the price target from $45 to $39.

Price Target

Goldman Sachs Maintains Neutral on Six Flags Entertainment, Lowers Price Target to $39

Goldman Sachs analyst Richard Law maintains Silence Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLN#NASDAQ">SLN</a>) with a Sell and lowers the price target from $4 to $3.

Goldman Sachs Maintains Sell on Silence Therapeutics, Lowers Price Target to $3

Goldman Sachs analyst Brooke Roach maintains SharkNinja (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SN#NYSE">SN</a>) with a Buy and raises the price target from $100 to $112.

Goldman Sachs Maintains Buy on SharkNinja, Raises Price Target to $112

Solo Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DTC#NYSE">DTC</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.
Analysts estimate that Solo Brands will report an earnings per share (EPS) of $-0.05. 
Anticipation surrounds Solo Brands's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Earnings Track Record</h3>
The company's EPS missed by $0.10 in the last quarter, leading to a 9.54% drop in the share price on the following day.
Here's a look at Solo Brands's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.13</td>
<td>0.02</td>
<td>0.13</td>
<td>0</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.03</td>
<td>0.02</td>
<td>0.04</td>
<td>0.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>-6.0%</td>
<td>8.0%</td>
<td>-2.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746814374_0.png" alt="eps graph" />
<h3>Market Performance of Solo Brands's Stock</h3>
Shares of Solo Brands were trading at $0.094 as of April 21. Over the last 52-week period, shares are down 95.3%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/DTC/earnings">To track all earnings releases for Solo Brands visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Earnings Preview: Solo Brands

Ispire Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ISPR#NASDAQ">ISPR</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Ispire Technology to report an earnings per share (EPS) of $-0.12.
Ispire Technology bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company missed EPS by $0.07, leading to a 1.83% drop in the share price the following trading session.
Here's a look at Ispire Technology's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2025</th>
<th>Q1 2025</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.07</td>
<td>-0.06</td>
<td>-0.09</td>
<td>0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.14</td>
<td>-0.10</td>
<td>-0.03</td>
<td>-0.11</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>2.0%</td>
<td>2.0%</td>
<td>6.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746814362_0.png" alt="eps graph" />
<h3>Performance of Ispire Technology Shares</h3>
Shares of Ispire Technology were trading at $2.9 as of May 08. Over the last 52-week period, shares are down 50.75%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analysts' Perspectives on Ispire Technology</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Ispire Technology.
The consensus rating for Ispire Technology is Buy, derived from 1 analyst ratings. An average one-year price target of $9.0 implies a potential 210.34% upside.
<h3>Peer Ratings Overview</h3>
In this analysis, we delve into the analyst ratings and average 1-year price targets of and Turning Point Brands, three key industry players, offering insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Outperform trajectory for Turning Point Brands, with an average 1-year price target of $85.0, suggesting a potential 2831.03% upside.</li>
</ul>
<h3>Snapshot: Peer Analysis</h3>
The peer analysis summary offers a detailed examination of key metrics for and Turning Point Brands, providing valuable insights into their respective standings within the industry and their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ispire Technology</td>
<td>Buy</td>
<td>0.34%</td>
<td>$7.72M</td>
<td>-29.11%</td>
</tr>
<tr>
<td>Turning Point Brands</td>
<td>Outperform</td>
<td>194.64%</td>
<td>$42.11M</td>
<td>1.30%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Ispire Technology ranks lower in revenue growth compared to its peer. It also has a lower gross profit margin. Additionally, its return on equity is negative, indicating lower profitability compared to its peer.
<h3>Unveiling the Story Behind Ispire Technology</h3>
Ispire Technology Inc is engaged in the research and development, design, commercialization, sales, marketing, and distribution of branded e-cigarettes and cannabis vaping products. The company sells its cannabis vaping in the United States, Europe, Canada, and South Africa.
<h3>Ispire Technology: A Financial Overview</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Ispire Technology's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 0.34%. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Consumer Staples sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Ispire Technology's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of -19.12%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Ispire Technology's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -29.11% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Ispire Technology's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -6.13% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: With a below-average debt-to-equity ratio of 0.12, Ispire Technology adopts a prudent financial strategy, indicating a balanced approach to debt management.
<a href="https://www.benzinga.com/quote/ISPR/earnings">To track all earnings releases for Ispire Technology visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ISPR

Insights into Ispire Technology's Upcoming Earnings

Goldman Sachs analyst Mark Delaney maintains Sensata Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ST#NYSE">ST</a>) with a Buy and raises the price target from $27 to $30.

Goldman Sachs Maintains Buy on Sensata Technologies, Raises Price Target to $30

Goldman Sachs analyst Richard Law maintains Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Neutral and lowers the price target from $15 to $13.

RCKT

Goldman Sachs Maintains Neutral on Rocket Pharmaceuticals, Lowers Price Target to $13

Village Farms Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VFF#NASDAQ">VFF</a>) will release its quarterly earnings report on Monday, 2025-05-12. Here's a brief overview for investors ahead of the announcement.
Analysts anticipate Village Farms Intl to report an earnings per share (EPS) of $0.00.
Village Farms Intl bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
The company's EPS missed by $0.06 in the last quarter, leading to a 2.84% increase in the share price on the following day.
Here's a look at Village Farms Intl's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.02</td>
<td>-0.03</td>
<td>-0.03</td>
<td>-0.02</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.08</td>
<td>-0.01</td>
<td>-0.10</td>
<td>-0.03</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-7.000000000000001%</td>
<td>-5.0%</td>
<td>4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746814289_0.png" alt="eps graph" />
<h3>Market Performance of Village Farms Intl's Stock</h3>
Shares of Village Farms Intl were trading at $0.6481 as of May 08. Over the last 52-week period, shares are down 48.5%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/VFF/earnings">To track all earnings releases for Village Farms Intl visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

An Overview of Village Farms Intl's Earnings

Goldman Sachs analyst Eric Sheridan maintains Peloton Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTON#NASDAQ">PTON</a>) with a Neutral and lowers the price target from $10 to $7.

PTON

Goldman Sachs Maintains Neutral on Peloton Interactive, Lowers Price Target to $7

Goldman Sachs analyst Duffy Fischer maintains Nutrien (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NTR#NYSE">NTR</a>) with a Sell and raises the price target from $53 to $59.

Goldman Sachs Maintains Sell on Nutrien, Raises Price Target to $59

On Thursday, U.S. Food and Drug Administration (FDA) Commissioner Martin A. Makary announced an aggressive timeline to scale the use of <a target="_blank" href="https://www.benzinga.com/topic/artificial-intelligence" rel="noreferrer noopener">artificial intelligence (AI)</a> internally across all FDA centers by June 30, following the completion of a new generative AI pilot for scientific reviewers.
Makary has <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-announces-completion-first-ai-assisted-scientific-review-pilot-and-aggressive-agency-wide-ai" rel="noreferrer noopener">directed</a> all FDA centers to begin deployment immediately, with the goal of full integration by the end of June. Work will continue to expand use cases, improve functionality, and adapt to the evolving needs of each center after June 30.
By that date, all centers will be operating on a common, secure generative AI system integrated with the FDA&#8217;s internal data platforms.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/03/44087329/microsoft-unveils-ai-powered-dragon-copilot-to-ease-clinician-workloads" rel="noreferrer noopener">Microsoft Unveils AI-Powered Dragon Copilot To Ease Clinician Workloads</a>
Makary spoke about the need to shorten the length of the drug approval process and the use of artificial intelligence, among other topics, during the AHA Annual Membership Meeting on Tuesday.
&#8220;We at the FDA now have to ask big questions that we&#8217;ve never asked before,&#8221; Makary <a target="_blank" href="https://www.aha.org/news/headline/2025-05-06-fda-commissioner-talks-shortening-drug-approval-process-benefits-ai" rel="noreferrer noopener">said</a>. &#8220;Why does it take over 10 years for a new drug to come to market? Why are we not modernized with AI and other things?&#8221;
Makary was also optimistic about AI helping to approve new treatments for conditions such as diabetes and certain types of cancer.
According to a media report on Wednesday, OpenAI, which is backed by Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), met with FDA officials to discuss the agency&#8217;s use of AI to speed up drug evaluations.
Makary didn&#8217;t say OpenAI was involved in the project, but sources familiar with it say a small team from OpenAI has met several times in recent weeks with the FDA and two associates from Elon Musk&#8217;s Department of Government Efficiency (DOGE).
They&#8217;ve been discussing a <a target="_blank" href="https://www.wired.com/story/openai-fda-doge-ai-drug-evaluation/" rel="noreferrer noopener">project</a> called &#8220;cderGPT,&#8221; likely referring to the FDA&#8217;s Center for Drug Evaluation and Research (CDER), which regulates over-the-counter and prescription drugs in the U.S., and &#8220;Research GPT.&#8221; Jeremy Walsh, the FDA&#8217;s newly appointed AI officer, has led the talks. No contract has been finalized yet.
According to the May 2024 McKinsey Global Institute report, AI technology could generate&nbsp;$60 billion—$110 billion annually in economic value for the pharmaceutical industry, as it can help speed up the process of identifying compounds, <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38768537/from-hype-to-reality-ai-reshapes-pharmaceutical-industry-across-drug-discovery-to-marketing-stock" rel="noreferrer noopener">their development, and approval</a>.
In May 2024, Researchers at&nbsp;Alphabet Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>)&nbsp;Google DeepMind developed AlphaFold 3, a new <a target="_blank" href="https://www.benzinga.com/general/biotech/24/05/38711266/google-deepmind-develops-latest-ai-model-to-aid-scientists-in-fighting-disease" rel="noreferrer noopener">artificial intelligence (AI) model</a>.
AlphaFold 3 can predict the structure and interactions of biological molecules. This includes proteins, DNA, and RNA, and small molecules that could function as drugs.&nbsp;
Google DeepMind will make the model available for non-commercial use through&nbsp;the AlphaFold server.&nbsp;
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/general/biotech/25/05/45324296/trump-cut-11-billion-in-local-government-fight-back" target="_blank" rel="noreferrer noopener">Trump Admin Cuts $11 Billion In Health Funds — Local Governments Fight Back</a></li>
</ul>
Photo by Tada Images via Shutterstock

GOOG

GOOGL

MSFT

Trump Appointed Martin Makary Targets Faster Drug Approvals With FDA Artificial Intelligence Overhaul

Goldman Sachs analyst Will Nance maintains NCR Voyix (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VYX#NYSE">VYX</a>) with a Neutral and raises the price target from $8.5 to $11.

Goldman Sachs Maintains Neutral on NCR Voyix, Raises Price Target to $11

Goldman Sachs analyst Kate McShane maintains National Vision Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYE#NASDAQ">EYE</a>) with a Neutral and raises the price target from $13 to $17.

Goldman Sachs Maintains Neutral on National Vision Holdings, Raises Price Target to $17

Aquestive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQST#NASDAQ">AQST</a>) is set to give its latest quarterly earnings report on Monday, 2025-05-12. Here's what investors need to know before the announcement.
Analysts estimate that Aquestive Therapeutics will report an earnings per share (EPS) of $-0.16. 
Aquestive Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
Last quarter the company missed EPS by $0.06, which was followed by a 7.53% drop in the share price the next day.
Here's a look at Aquestive Therapeutics's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.13</td>
<td>-0.13</td>
<td>-0.12</td>
<td>-0.08</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.19</td>
<td>-0.13</td>
<td>-0.03</td>
<td>-0.17</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-8.0%</td>
<td>-8.0%</td>
<td>1.0%</td>
<td>-9.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746814019_0.png" alt="eps graph" />
<h3>Aquestive Therapeutics Share Price Analysis</h3>
Shares of Aquestive Therapeutics were trading at $2.76 as of May 08. Over the last 52-week period, shares are down 14.83%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/AQST/earnings">To track all earnings releases for Aquestive Therapeutics visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AQST

Uncovering Potential: Aquestive Therapeutics's Earnings Preview

Goldman Sachs analyst Lizzie Dove maintains Marriott Vacations (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VAC#NYSE">VAC</a>) with a Sell and raises the price target from $48 to $55.

Goldman Sachs Maintains Sell on Marriott Vacations, Raises Price Target to $55

United Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBCP#NASDAQ">UBCP</a>) reported quarterly earnings of $0.32 per share. This is a 8.57 percent decrease over earnings of $0.35 per share from the same period last year. The company reported $7.53 million in sales this quarter. This is a 7.84 percent increase over sales of $6.98 million the same period last year.

UBCP

United Bancorp Q1 EPS $0.32 Down From $0.35 YoY, Sales $7.53M Up From $6.98M YoY

In March, the U.S. Department of Health and Human Services (HHS) unveiled a sweeping restructuring plan to cut costs, streamline <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">operations, and refocus priorities</a>.
Congress has long considered HHS vital to national well-being, appropriating $2.5 trillion for Fiscal Year 2024 to support its broad mandate across medicine, public health and social services.
The changes, aligned with President Donald Trump's executive order on government efficiency, will reduce the agency&#8217;s workforce, consolidate divisions and emphasize efforts to <a href="https://www.benzinga.com/government/regulations/25/03/44519638/us-department-of-health-and-human-services-aligns-with-trumps-executive-order-to-cut-10k-jobs-save-18-billion" target="_blank" rel="noreferrer noopener">combat chronic illness</a>.
The&nbsp;restructuring&nbsp;will reduce the HHS workforce by 10,000 full-time employees, leading to annual savings of $1.8 billion.
<ul class="wp-block-list">
<li>Through early retirements and other initiatives, the total number of employees will shrink from 82,000 to 62,000.</li>
</ul>
Multiple states have <a target="_blank" href="https://www.njoag.gov/wp-content/uploads/2025/05/2025-0505_State-of-New-York-v.-Kennedy-Jr.pdf" rel="noreferrer noopener">filed</a> legal challenges to Secretary Robert F. Kennedy Jr.&#8217;s reorganization, arguing that the moves violate constitutional mandates and congressional intent.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/25/01/43038618/hhs-challenges-vertex-over-fertility-services-program-tied-to-casgevy-gene-therapy" rel="noreferrer noopener">HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is &#8216;Grasping at Straws&#8217;</a>
The states claim the administration's efforts have dismantled the agency in defiance of established laws, severely disrupting health programs critical to Americans nationwide.
In a lawsuit filed on Monday, the states said the sudden layoffs brought HHS operations to a near standstill.
Laboratories stopped testing for infectious diseases, FDA vaccine reviews were missed and vital programs such as Head Start and the Low-Income Home Energy Assistance Program were left unsupported.
The World Trade Center Health Program could no longer certify illnesses and maternal health initiatives were shut down. Meanwhile, grantees and state partners were left without contacts or guidance as key portals and support channels went dark.
Although the terminations affected many employees, the cuts disproportionately targeted specific agencies, including the Centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), the Substance Abuse and Mental Health Services Administration (SAMHSA), the Administration for Children and Families (ACF), and the Administration for Community Living (ACL).
20,000 positions—almost a quarter of the HHS workforce—are slated for elimination. Despite the scale, Kennedy reportedly acknowledged that up to 20% of the layoffs were known to be mistakes even before execution.
Kennedy admitted that the decision to forgo a detailed review was driven by a desire to preserve "political momentum."
Importantly, the downsizing was not necessitated by budget constraints—congressional funding has remained stable or increased.
States argue the move was a deliberate effort to sideline the department's role, defying the very laws and mandates that created and funded it. The chaotic restructuring has left the remaining staff unable to process grants, issue funds, review policies, or manage public health emergencies.
In response, Plaintiff States are pursuing declaratory and injunctive relief to halt what they describe as the unlawful dismantling of one of the federal government's most complex and essential departments.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45297979/whats-going-on-with-us-foods-stock-on-thursday" target="_blank" rel="noreferrer noopener">US Foods Dishes Out 40% Net Income Gain, Readies $1 Billion Buyback</a></li>
</ul>
Photo: Shutterstock

Government

Health Care

Politics

Legal

General

Trump's HHS Overhaul Faces Legal Blowback From States Over Deep Staffing Cuts, Slashed Health Programs

Goldman Sachs analyst Michael Ng maintains Ingram Micro Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/INGM#NYSE">INGM</a>) with a Buy and lowers the price target from $29 to $25.

INGM

Goldman Sachs Maintains Buy on Ingram Micro Holding, Lowers Price Target to $25

Telsey Advisory Group analyst Dana Telsey reiterated the Outperform rating on Birkenstock Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIRK#NYSE">BIRK</a>) <a target="_blank" href="https://www.benzinga.com/quote/BIRK/analyst-ratings" rel="noreferrer noopener">with a price forecast of $70</a>.
The company is set to report its second-quarter results on May 15, <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/ac44808411/birkenstock-announces-fiscal-second-quarter-2025-ended-march-31-2025-results-date-and-conference-" rel="noreferrer noopener">before the market opens.</a>
Telsey projects total revenue to grow 17.7% year-over-year to 566.4 million euros, slightly trailing the consensus estimate of 568.2 million euros.
The analyst sees a 30-basis-point expansion in gross margin to 56.6%, narrowly topping the consensus forecast of 56.5%, which implies a 20-basis-point improvement.
Also Read: <a target="_blank" href="http://benzinga.com/25/03/44360179/birkenstock-eyes-rapid-growth-targeting-us-and-global-retail-markets-says-analyst" rel="noreferrer noopener">Birkenstock's US Expansion Has Significant Upside With Fewer Than 10 Stores Today, Analyst Says</a>
Additionally, Telsey analyst pointed out that Birkenstock holds a relative advantage in terms of tariff exposure, as the company manufactures in Germany and only derives 52% of its fiscal 2024 revenue from the Americas, limiting its vulnerability compared to peers in the footwear industry.
The analyst also anticipates that operating expenses will remain flat year-over-year at 27.6%, which is slightly below the consensus figure of 27.7%, reflecting a minor 10-basis-point deleverage.
In aggregate, Telsey forecasts a 180-basis-point improvement in pretax profit margin to 24.8%, which comes in just under the Street's expectation of a 230-basis-point rise to 25.3%.
For the fiscal second quarter, Telsey maintains an adjusted EBITDA estimate of 193.3 million euros, up from 162.3 million euros in the prior-year quarter and closely aligned with the consensus view of €192.9 million.
This projection corresponds to an adjusted EBITDA margin of 34.1%.
Telsey noted that the brand is maintaining strong demand across multiple regions and distribution channels, continuing to execute well despite ongoing global macroeconomic challenges.
The analyst also highlighted the firm's successful efforts in expanding its closed-toe shoe segment across different markets while also driving average selling price growth.
As consumers become more selective with their spending, Telsey sees Birkenstock as a brand well-positioned to thrive due to its premium lifestyle appeal and distinct focus on comfort, a value proposition that's difficult for competitors to replicate.
Price Action: BIRK shares are trading lower by 0.36% to $52.28 at the last check on Friday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44800974/consumers-go-discount-as-tariff-pressures-mount-warns-analyst" target="_blank" rel="noreferrer noopener">Consumers Go Discount As Tariff Pressures Mount, Warns Analyst</a></li>
</ul>
Photo by Josh Forden via Shutterstock

Comments

Lanvin Gr Hldgs

Lanvin Gr Hldgs (LANV) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL